CI

At a glance

ClinicalIndex Comparison Record
Phase 4Unknown· 2,509 enrolled
Drug / intervention
Clopidogrel & Aspirin, Prasugrel & Aspirin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00954707
NCT00954707Phase 4Unknown

A Prospective, Randomized, Multi-Center, Double-Blind Trial to Assess the Effectiveness and Safety of Different Durations of Dual Anti-Platelet Therapy (DAPT) in Subjects Undergoing Percutaneous Coronary Intervention With the CYPHER® Sirolimus-eluting Coronary Stent (CYPHER® Stent)

Cordis US Corp.·interventional·Posted Aug 7, 2009·Updated Feb 7, 2014

In Brief

A Phase 4 clinical trial evaluating Clopidogrel & Aspirin, Prasugrel & Aspirin and Placebo & Aspirin for Coronary Artery Disease. Targeting 2,509 participants across 1 site.

Detailed Summary

CYPRESS: A Prospective,Randomized,Multi-Center,Double-Blind Trial to Assess the Effectiveness and Safety of Different Durations of Dual Anti-Platelet Therapy (DAPT) in Subjects Undergoing Percutaneous Coronary Intervention with the CYPHER® Sirolimus-eluting Coronary Stent (CYPHER® Stent)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 4UnknownOverdue
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 7, 2009
Enrollment StartAug 1, 2009
Primary CompletionJan 1, 2012
Study CompletionMar 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 16.9 years ago

Interventions

Clopidogrel & Aspirin, Prasugrel & Aspirindrug

This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of thienopyridine treatment in addition to aspirin.

Placebo & Aspirindrug

This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of placebo treatment in addition to aspirin.